Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 160,000 shares at $71.80 ($11.5M) on 2026-02-10, disclosed to the SEC on 2026-02-12.
Seasonal sale ($11.5M) by Chief Executive Officer — this insider has traded BBIO in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $71.80 | 14,040 | $1.0M | 8.8% |
| 2 | $71.80 | 14,201 | $1.0M | 8.9% |
| 3 | $71.80 | 14,040 | $1.0M | 8.8% |
| 4 | $71.80 | 14,201 | $1.0M | 8.9% |
| 5 | $72.27 | 5,960 | $431K | 3.7% |
| 6 | $72.27 | 5,960 |
| $431K |
| 3.7% |
| 7 | $72.28 | 5,799 | $419K | 3.6% |
| 8 | $72.28 | 5,799 | $419K | 3.6% |
| 9 | $70.69 | 7,806 | $552K | 4.8% |
| 10 | $70.69 | 7,806 | $552K | 4.8% |
| 11 | $70.70 | 7,860 | $556K | 4.8% |
| 12 | $70.70 | 7,860 | $556K | 4.8% |
| 13 | $71.44 | 3,716 | $265K | 2.3% |
| 14 | $71.44 | 3,716 | $265K | 2.3% |
| 15 | $71.46 | 3,775 | $270K | 2.3% |
| 16 | $71.46 | 3,775 | $270K | 2.3% |
| 17 | $72.64 | 4,484 | $326K | 2.8% |
| 18 | $72.64 | 4,484 | $326K | 2.8% |
| 19 | $72.65 | 4,404 | $320K | 2.8% |
| 20 | $72.65 | 4,404 | $320K | 2.8% |
| 21 | $73.25 | 3,961 | $290K | 2.5% |
| 22 | $73.25 | 3,994 | $293K | 2.5% |
| 23 | $73.25 | 3,961 | $290K | 2.5% |
| 24 | $73.25 | 3,994 | $293K | 2.5% |
| Total | $71.86 avg | 160,000 | $11.5M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |